PCM
RARE icon

Prelude Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Prelude Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,800
Closed -$219K – 2251
2020
Q2 		$219K Hold
2,800
– – 0.01% 714
2020
Q1 		$124K Buy
+2,800
New +$145K 0.01% 547
2017
Q3 		– Sell
-8,000
Closed -$497K – 1855
2017
Q2 		$497K Buy
+8,000
New +$482K 0.05% 333

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's RARE Position: Q3 2025 in Review

Prelude Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 12,681 shares — an estimated $461K sold.

Prelude Capital Management first reported a position in RARE in Q1 2016 and held it in 15 quarters. The position peaked at $999K in Q1 2024. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Prelude Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 12,681 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $461K.
  • Prelude Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 15 quarters.
  • Prelude Capital Management's Ultragenyx Pharmaceutical position peaked at $999K in Q1 2024.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.